https://scholars.lib.ntu.edu.tw/handle/123456789/487343
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | CHIA-CHI LIN | en_US |
dc.contributor.author | KUN-HUEI YEH | en_US |
dc.contributor.author | CHIH-HSIN YANG | en_US |
dc.contributor.author | CHIUN HSU | en_US |
dc.contributor.author | YU-CHIEH TSAI | en_US |
dc.contributor.author | Hsu W.-L. | en_US |
dc.contributor.author | ANN-LII CHENG | en_US |
dc.contributor.author | CHIH-HUNG HSU | en_US |
dc.creator | CHIH-HUNG HSU;Cheng A.-L.;Hsu W.-L.;Tsai Y.-C.;Hsu C.;Yang C.-H.;Yeh K.-H.;Lin C.-C. | - |
dc.date.accessioned | 2020-04-28T07:25:31Z | - |
dc.date.available | 2020-04-28T07:25:31Z | - |
dc.date.issued | 2007 | - |
dc.identifier.issn | 0959-4973 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-34548244012&doi=10.1097%2fCAD.0b013e328051b3a3&partnerID=40&md5=d0f0597a6ed5dd6b642fa7471994823a | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/487343 | - |
dc.description.abstract | This study assessed the clinical activity and safety of twice-weekly paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin (TP-HDFL) in patients with recurrent or metastatic esophageal squamous cell carcinoma. The regimen, composed of paclitaxel 35 mg/m 1-h intravenous infusion on days 1, 4, 8 and 11; cisplatin 20 mg/m 2-h intravenous infusion on days 2, 5, 9 and 12; and 5-flourouracil 2000 mg/m and leucovorin 300 mg/m 24-h intravenous infusion on days 5 and 12; repeated every 21 days. Forty-one patients (median age 51), 15 with de-novo metastatic disease and 26 with recurrent disease, were enrolled. Grades 3-4 neutropenia, leukopenia and diarrhea occurred in 37.8, 29.4 and 14.2% of cycles, respectively. One patient died of invasive fungal infection. Three complete responses, 13 partial response and 13 stable diseases were observed. The intent-to-treat response rate was 39.0% (95% confidence interval: 24-54). The median progression-free and overall survival were 6.3 and 8.9 months (range 1-50+), respectively. Twice-weekly TP-HDFL has the activity and toxicity profile similar to the previously reported same three-drug combination for advanced esophageal cancer. ? 2007 Lippincott Williams & Wilkins, Inc. | - |
dc.relation.ispartof | Anti-Cancer Drugs | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | cisplatin; dexamethasone; diphenhydramine; fluorouracil; folinic acid; paclitaxel; ranitidine; adult; alopecia; article; cancer combination chemotherapy; clinical article; clinical trial; confidence interval; continuous infusion; controlled study; diarrhea; drug activity; drug response; drug safety; esophageal squamous cell carcinoma; female; human; infection; leukopenia; liver toxicity; male; metastasis; mucosa inflammation; multiple cycle treatment; nausea and vomiting; nephrotoxicity; neurotoxicity; neutropenia; overall survival; priority journal; recurrent cancer; risk assessment; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel | - |
dc.title | Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1097/CAD.0b013e328051b3a3 | - |
dc.identifier.pmid | 17762400 | - |
dc.identifier.scopus | 2-s2.0-34548244012 | - |
dc.relation.pages | 703-708 | - |
dc.relation.journalvolume | 18 | - |
dc.relation.journalissue | 6 | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Cancer Administration and Coordination Center | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Cancer Administration and Coordination Center | - |
crisitem.author.dept | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Medical Oncology-NTUCC | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Medical Oncology-NTUCC | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Cancer Administration and Coordination Center | - |
crisitem.author.orcid | 0000-0002-7306-174X | - |
crisitem.author.orcid | 0000-0002-5586-5138 | - |
crisitem.author.orcid | 0000-0002-1122-0055 | - |
crisitem.author.orcid | 0000-0002-9285-7655 | - |
crisitem.author.orcid | 0000-0002-9152-6512 | - |
crisitem.author.orcid | 0000-0003-0495-973X | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。